Cara Therapeutics Inc CARA
$5.32 $0.23 (4.14%) 1D
Last Updated: Apr 15, 12:00 AM·BE
Pricing for DE stocks is delayed by 24 hours
Open navigation menu
Invest
Invest on your own
We do it for you
Halal tools
Screeners
Your portfolio
Calculators
Shariah
Our certifications
Learn
Education
Get help
Pricing
Company
About Musaffa
Investors
Build with us
Is Cara Therapeutics Inc Stock Halal?
Shariah Compliance Analysis of CARA Stock
Germany Health Care Nano Cap No. As of September 2026, Cara Therapeutics Inc (CARA) is classified as NOT HALAL by Musaffa under its AAOIFI-based Shariah screening methodology. Cara Therapeutics Inc does not pass Musaffa's business and financial screening criteria.
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The company is headquartered in Stamford, Connecticut and currently employs 10 full-time employees. The company went IPO on 2014-01-31. The firm is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. The company is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. The company is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. The company has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
CARA Shariah Compliance
Screening Methodology: AAOIFI
As of September 2026, Cara Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Cara Therapeutics Inc (CARA) Chart
Financial Metrics & Statements of Cara Therapeutics Inc (CARA)
FAQ's for Cara Therapeutics Inc (CARA)
- As of September 2026, Cara Therapeutics Inc CARA is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Cara Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Cara Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Cara Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Cara Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Cara Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Cara Therapeutics Inc (CARA)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
